C4 Therapeutics, Inc.
Symbol: CCCC (NASDAQ)
Company Description:
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
- Today's Open: $2.165
- Today's High: $2.185
- Today's Low: $2.115
- Today's Volume: 197.98K
- Yesterday Close: $2.05
- Yesterday High: $2.2
- Yesterday Low: $2.03
- Yesterday Volume: 499.51K
- Last Min Volume: 2
- Last Min High: $2.16
- Last Min Low: $2.16
- Last Min VWAP: $2.16
- Name: C4 Therapeutics, Inc.
- Website: https://www.c4therapeutics.com
- Listed Date: 2020-10-02
- Location: WATERTOWN, MA
- Market Status: Active
- CIK Number: 0001662579
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $150.54M
- Round Lot: 100
- Outstanding Shares: 71.01M
- Asset Type: CS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-07-16 | SCHEDULE 13G/A | View |
| 2025-07-15 | 4/A | View |
| 2025-07-14 | 4 | View |
| 2025-07-02 | 4 | View |
| 2025-07-02 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-18 | 8-K | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-07 | SCHEDULE 13G/A | View |
| 2025-05-07 | 10-Q | View |
| 2025-05-07 | 8-K | View |
| 2025-04-29 | ARS | View |